Now Available

Horizon™ Carrier Screen with Fetal Focus™

Direct fetal insights for inherited single-gene conditions from the maternal carrier’s sample

Flexibility to meet your prenatal patient needs

Fetal Focus™, a noninvasive prenatal test (NIPT) for inherited conditions, screens the fetus for five genes after Horizon™ carrier screen identifies the patient as a carrier: Cystic fibrosis (CFTR), alpha-thalassemia (HBA1/HBA2), spinal muscular atrophy (SMN1), beta-hemoglobinopathies (HBB) including sickle cell disease*

*Fetal Focus™ is available with Horizon a la carte (individual orders of cystic fibrosis and spinal muscular atrophy), H4, Hbasic, H14, H27, H106, and H274
Fetal Focus™ is not currently available to order in New York State. We will provide updates when the test becomes available.

Fetal risk assessment without requiring a partner sample

Screening affected pregnancies across diverse populations

†Fetal Focus™ is a screening test, not a diagnostic test. False positive and false negative results can occur. A high risk result does not mean the fetus is affected. Similarly, a low risk result does not definitively mean the fetus is unaffected. Genetic counseling and diagnostic testing should be offered to further evaluate high risk results.

John Williams, M.D.

Chief principal investigator for EXPAND and director of reproductive genetics at Cedars-Sinai

Having access to a noninvasive option like Fetal Focus™ can provide critical information to support decision-making during pregnancy, especially in situations where partner testing isn’t possible

Improved detection with the proprietary LinkedSNP™ technology

Watch how LinkedSNP^TM technology utilizes SNP markers, comprehensive NGS sequencing, and bioinformatic models to enhance detection of the disease-causing variants, regardless of ancestry

Available with the #1 ordered NIPT and carrier screen³

In one blood draw, your patients receive the pioneering SNP-based Panorama™ NIPT and comprehensive Horizon™ carrier screening with Fetal Focus™ as an add-on

Inform decisions about Rh immune globulin with Fetal RhD NIPT
Distinguish the viable twin from the vanished twin

Learn how Fetal Focus™ can be integrated in your practice

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Internal data on file from EXPAND clinical study. In EXPAND, the study participants and investigators are blinded to the Fetal Focus^TM test results.
²Expanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). https://clinicaltrials.gov/study/NCT06808880.Accessed July 2025.
³Internal analysis of Denitive Healthcare database and ancillary data. Dec 2023.